Nakata M, Mukawa J, Miyagi K, Kinjou T, Sakuta O, Miyazato H, Okuyama K, Higa Y, Terada Y
Department of Neurosurgery, University of The Ryukyus.
Jpn J Antibiot. 1990 Jun;43(6):1174-80.
Cefbuperazone (CBPZ) was given in 15 patients after surgery. There was no infections except for 1 case in which signs of infections were suspected. As side effects, slight elevations in hepatic transaminase levels were observed in 3 patients during the CBPZ chemotherapy. CBPZ concentrations in 7 patients were studied. The subjects were divided into 3 groups according to CT finding during the chemotherapy to correlate CBPZ concentrations to degrees of blood-brain barrier lesions; Group I: no enhancement, Group II: mild or focal enhancement, Group III: diffuse and marked enhancement. It was interesting to note that the more marked enhancement were obtained, the higher levels of CSF concentration of CBPZ.
15例患者术后给予头孢哌酮钠舒巴坦钠（CBPZ）。除1例疑似感染迹象外，无感染发生。作为副作用，3例患者在CBPZ化疗期间观察到肝转氨酶水平轻度升高。研究了7例患者的CBPZ浓度。根据化疗期间的CT表现将受试者分为3组，以将CBPZ浓度与血脑屏障损伤程度相关联；第一组：无强化，第二组：轻度或局灶性强化，第三组：弥漫性和明显强化。值得注意的是，强化越明显，CBPZ的脑脊液浓度水平越高。
